244 related articles for article (PubMed ID: 28282600)
1. Determination of free polysaccharide in Vi glycoconjugate vaccine against typhoid fever.
Giannelli C; Cappelletti E; Di Benedetto R; Pippi F; Arcuri M; Di Cioccio V; Martin LB; Saul A; Micoli F
J Pharm Biomed Anal; 2017 May; 139():143-147. PubMed ID: 28282600
[TBL] [Abstract][Full Text] [Related]
2. The need & the issues related to new-generation typhoid conjugate vaccines in India.
Vashishtha VM; Kalra A
Indian J Med Res; 2020 Jan; 151(1):22-34. PubMed ID: 32134011
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM(197) glycoconjugate vaccine against Salmonella Typhi.
Rondini S; Micoli F; Lanzilao L; Pisoni I; Di Cioccio V; Saul AJ; Martin LB
J Infect Dev Ctries; 2012 Nov; 6(11):763-73. PubMed ID: 23277501
[TBL] [Abstract][Full Text] [Related]
4. Spectroscopic characterisation of a series of Salmonella Typhi Vi-diphtheria toxoid glycoconjugate antigens differing in polysaccharide-protein ratio.
Jones C; An SJ; Yoon YK; Kothari S; Sahastrabuddhe S; Carbis R
J Pharm Biomed Anal; 2020 Mar; 181():113100. PubMed ID: 31991319
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of two WHO First International Standards for Vi polysaccharide from Citrobacter freundii and Salmonella enterica subspecies enterica serovar Typhi.
Gao F; Swann C; Rigsby P; Rijpkema S; Lockyer K; Logan A; Bolgiano B;
Biologicals; 2019 Jan; 57():34-45. PubMed ID: 30502020
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi.
Rondini S; Micoli F; Lanzilao L; Hale C; Saul AJ; Martin LB
Clin Vaccine Immunol; 2011 Mar; 18(3):460-8. PubMed ID: 21248155
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
Jin C; Gibani MM; Moore M; Juel HB; Jones E; Meiring J; Harris V; Gardner J; Nebykova A; Kerridge SA; Hill J; Thomaides-Brears H; Blohmke CJ; Yu LM; Angus B; Pollard AJ
Lancet; 2017 Dec; 390(10111):2472-2480. PubMed ID: 28965718
[TBL] [Abstract][Full Text] [Related]
8. The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi.
Arcuri M; Di Benedetto R; Cunningham AF; Saul A; MacLennan CA; Micoli F
PLoS One; 2017; 12(12):e0189100. PubMed ID: 29287062
[TBL] [Abstract][Full Text] [Related]
9. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of typhoid vaccines against culture-confirmed Salmonella Typhi in typhoid endemic countries: a systematic review and meta-analysis.
Batool R; Qamar ZH; Salam RA; Yousafzai MT; Ashorn P; Qamar FN
Lancet Glob Health; 2024 Apr; 12(4):e589-e598. PubMed ID: 38485426
[TBL] [Abstract][Full Text] [Related]
11. Status of paratyphoid fever vaccine research and development.
Martin LB; Simon R; MacLennan CA; Tennant SM; Sahastrabuddhe S; Khan MI
Vaccine; 2016 Jun; 34(26):2900-2902. PubMed ID: 27083427
[TBL] [Abstract][Full Text] [Related]
12. IgA and IgG1 Specific to Vi Polysaccharide of
Dahora LC; Jin C; Spreng RL; Feely F; Mathura R; Seaton KE; Zhang L; Hill J; Jones E; Alam SM; Dennison SM; Pollard AJ; Tomaras GD
Front Immunol; 2019; 10():2582. PubMed ID: 31781100
[TBL] [Abstract][Full Text] [Related]
13. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children.
Szu SC; Klugman KP; Hunt S
Vaccine; 2014 Apr; 32(20):2359-63. PubMed ID: 24630869
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
[TBL] [Abstract][Full Text] [Related]
15. Immunization with the conjugate vaccine Vi-CRM₁₉₇ against Salmonella typhi induces Vi-specific mucosal and systemic immune responses in mice.
Fiorino F; Ciabattini A; Rondini S; Pozzi G; Martin LB; Medaglini D
Vaccine; 2012 Sep; 30(43):6111-4. PubMed ID: 22705173
[TBL] [Abstract][Full Text] [Related]
16. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
An SJ; Scaria PV; Chen B; Barnafo E; Muratova O; Anderson C; Lambert L; Chae MH; Yang JS; Duffy PE
Vaccine; 2018 May; 36(21):2978-2984. PubMed ID: 29681410
[TBL] [Abstract][Full Text] [Related]
17. Vi polysaccharide and conjugated vaccines afford similar early, IgM or IgG-independent control of infection but boosting with conjugated Vi vaccines sustains the efficacy of immune responses.
Jossi SE; Arcuri M; Alshayea A; Persaud RR; Marcial-Juárez E; Palmieri E; Di Benedetto R; Pérez-Toledo M; Pillaye J; Channell WM; Schager AE; Lamerton RE; Cook CN; Goodall M; Haneda T; Bäumler AJ; Jackson-Jones LH; Toellner KM; MacLennan CA; Henderson IR; Micoli F; Cunningham AF
Front Immunol; 2023; 14():1139329. PubMed ID: 37033932
[TBL] [Abstract][Full Text] [Related]
18. Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV).
Voysey M; Pollard AJ
Clin Infect Dis; 2018 Jun; 67(1):18-24. PubMed ID: 29351594
[TBL] [Abstract][Full Text] [Related]
19. Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype?
Pulickal AS; Pollard AJ
Expert Rev Vaccines; 2007 Jun; 6(3):293-5. PubMed ID: 17542742
[No Abstract] [Full Text] [Related]
20. Phase I clinical trial of O-acetylated pectin conjugate, a plant polysaccharide based typhoid vaccine.
Szu SC; Lin KF; Hunt S; Chu C; Thinh ND
Vaccine; 2014 May; 32(22):2618-22. PubMed ID: 24657719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
